Modified HIV-1gag p17 peptide and immunogenic composition
AssigneeBionor Immuno AS
InventorBirger Sorensen
Life of this patent
Estimating the term…
Abstract
The present invention comprises novel and modified peptides capable of inducing a HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p17 and p24 proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.
Claims7
An isolated HIV-1 gag p17 peptide comprising the amino acid sequence of SEQ ID NO:
- 3, wherein the terminal ends of the sequence may be free carboxyl- or amino groups, amides, acyls, acetyls or salts thereof and/or the sequence is immobilized to a solid support.
Dependencies are inferred from the claim text.